The Mission of GENECAST, an Early Cancer Detection Firm
GENECAST devotes everything to early cancer detection.
Early detection is our sole weapon for conquering cancer. Stage III stomach cancer has a survival rate of merely 6% But if discovered in Stage I, the survival rate skyrockets to 96%.
If everyone can receive fast and accurate cancer diagnoses, We no longer need to live in fear of cancer.
GENECAST’s solution is liquid biopsy.
Liquid biopsy is a novel, revolutionary analytic method that analyzes mutant tumor DNA in our blood to diagnose cancers. With only a simple blood draw, anyone can benefit from early cancer detection without any difficulty
The crux of early cancer detection through liquid biopsy is detection sensitivity.
Since mutant tumor DNA exists in such low quantities in blood, sensitivity can make or break diagnostic accuracy. To diagnose early cancers with liquid biopsy, a sensitivity of 1/100,000 is required. Existing liquid biopsy technologies offer at best 1/10,000.
Open a new era in cancer diagnostics with 1/1,000,000 sensitivity
GENECAST has developed ADPS(Allele-Discriminating Priming System), a early cancer detection platform boasting sensitivity 10 times greater than the minimum requirement for successful diagnosis.
ADPS is a accurate cancer diagnostic platform that selectively amplifies only mutant DNA, eliminating risks of false positives and false negatives